Metastatic prostate cancer patients’ Attitudes towards Treatment of the local Tumour and metastasis Evaluative Research (IP5-MATTER): A multicentre, discrete choice experiment trial-in-progress
Martin J. Connor(Imperial College Healthcare NHS Trust), Hashim U. Ahmed(National Health Service), Mark Beresford(Royal United Hospital Bath NHS Trust), Angus Robinson(Royal Sussex County Hospital), Gail Horan(Queen Elizabeth Hospital King's Lynn NHS Foundation Trust), Natalia Klimowska‐Nassar(Imperial College London), Mathias Winkler(National Health Service), Tim Dudderidge(University Hospital Southampton NHS Foundation Trust), Verity Watson(University of Aberdeen), Johanna Sukumar(Imperial College London), Feargus Hosking‐Jervis(Imperial College London), Naveed Sarwar(Imperial College Healthcare NHS Trust), Stephen Mangar(Imperial College Healthcare NHS Trust), Alison Falconer(Imperial College Healthcare NHS Trust), T. V. Pokrovska(Imperial College Healthcare NHS Trust), Vincent Khoo(The University of Texas MD Anderson Cancer Center), Mesfin G. Genie(Duke University), K. Thippu Jayaprakash(Queen Elizabeth Hospital King's Lynn NHS Foundation Trust), Michael Gonzalez(Imperial College Healthcare NHS Trust), Dolan Basak(Imperial College Healthcare NHS Trust)
Cited by 1
Related Papers
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
|The Lancet|2017|3.2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Multiple newly identified loci associated with prostate cancer susceptibility
|Nature Genetics|2008|850
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767